8/1/2016 | PP | Palatin Technologies conducts $9.25 million public offering of units
|
7/6/2015 | PP | Palatin wraps $30 million private placement of warrants, venture loan
|
12/24/2014 | PP | Palatin wraps $30 million private placement of stock, venture loan
|
10/9/2014 | PP | Palatin to sell $45 million of common stock through public offering
|
9/29/2014 | PP | Palatin Technologies to sell common stock through public offering
|
7/2/2012 | PP | Palatin Technologies negotiates $35 million private placement of stock
|
6/25/2010 | PP | New Issue: Palatin Technologies orchestrates $2 million direct offering of units
|
6/25/2010 | PP | Market Commentary: Golden Band seeks C$7 million; PokerTek arranges share offering; Iberian closes debenture sale
|
6/25/2010 | PP | Market Commentary: Golden Band seeks C$7 million; PokerTek arranges share offering; Iberian closes debenture sale
|
2/26/2010 | PP | New Issue: Palatin Technologies details $2.6 million direct offering of units
|
2/25/2010 | PP | New Issue: Palatin Technologies negotiates $2.59 million direct offering of units
|
2/25/2010 | PP | Market Commentary: Stella-Jones offers subscription receipts; Rainy River places units; Quetzal seeks funds
|
9/28/2007 | CV | Palatin Technologies files $50 million shelf
|
11/10/2006 | BT | Palatin's net loss for the first quarter up at $8.4 million due to bremelanotide development
|
9/27/2006 | BT | Palatin to start phase 3 bremelanotide trial in Q1 2007
|
9/13/2006 | BT | Palatin ends year with $30.7 million, reports no product sales for the quarter
|
8/9/2006 | BT | Market Commentary: Palatin up; Genaera gouged by reverse split plans; Onyx off; RegeneRx up; KOS up
|
6/22/2006 | BT | Palatin, King Pharmaceuticals say bremelanotide helps sexual dysfunction patients
|
5/4/2006 | BT | Palatin, King complete enrollment in two phase 2b trials of bremelanotide in erectile dysfunction patients
|
4/13/2006 | PP | Market Commentary: U.S. Energy secures $50 million equity line; Katanga Mining prices C$101.5 million PIPE
|
4/12/2006 | BT | Market Commentary: Vanda, Targacept tank on debut; Omrix IPO in limbo; Novavax, KOS climb; Discovery soars after hours
|
4/12/2006 | PP | Market Commentary: Hemispherx obtains $50 million equity line; Palatin Technologies will close $26.84 million unit sale
|
4/12/2006 | BTPP | New Issue: Palatin Technologies secures $26.84 million from direct unit deal
|
3/13/2006 | BTCV | Palatin Technologies files $50 million shelf
|
2/7/2006 | BT | Palatin, King start phase 2b clinical trial evaluating PT-141 in sexual arousal disorder patients
|
12/23/2005 | BT | Palatin, King terminate sublicense of Palatin, Competitive Technologies patents
|
9/30/2005 | BTPP | New Issue: Palatin Technologies completes $10 million private placement
|